Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06018025 · ClinicalTrials.gov registry record
NDPH Biomarker Study in Children and Adolescents
A clinical trial of New Persistent Daily Headache, sponsored by Duke University.
- Completed
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT06018025: Completed study of New Persistent Daily Headache, sponsored by Duke University.
NCT06018025 is a study of New Persistent Daily Headache that has completed, run by Duke University. The registered enrollment target is 38 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06018025, a study of New Persistent Daily Headache, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will recruit pediatric patients with NDPH (New Daily Persistent Headache), characterize their headache in a standard manner, and treat the NDPH with standard medications used for treatment of headaches in this population. Response to treatment with CGRP blocking Ab medications will be evaluated. Biomarkers related to headache disorders will be measured before and after treatment.
Primary Outcome
biomarker
Conditions Studied
Interventions
- DRUG CGRP antibody
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-04-15 |
| Est. Completion | 2025-05-29 |
What the finished NCT06018025 record still lists
NCT06018025 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 1 condition, with New Persistent Daily Headache appearing as the primary indexed condition, and to 1 intervention - of which CGRP antibody is the first listed.
NCT06018025 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06018025 about?
NCT06018025 is a clinical study titled "NDPH Biomarker Study in Children and Adolescents". This study will recruit pediatric patients with NDPH (New Daily Persistent Headache), characterize their headache in a standard manner, and treat the NDPH with standard medications used for treatment of headaches in this population. Response to treatment with CGRP blocking Ab medications will be eva...
What is the current status of trial NCT06018025?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2024-04-15. Estimated completion is 2025-05-29.
What conditions does trial NCT06018025 study?
This clinical trial studies the following conditions: New Persistent Daily Headache.
What interventions are being tested in trial NCT06018025?
The interventions under investigation include: CGRP antibody (DRUG).
Who is sponsoring clinical trial NCT06018025?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06018025 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI